ImmunGene granted a subsidiary of Cephalon rights to use its interferon payload drug delivery technology for cancer drug targets

ImmunGene Inc.

U.S. / Private Biopharma

Licensor

This is a sample profile. To view the full content of this profile and many others, log in to BCIQ or sign up for a free trial today!

Cephalon Inc.

U.S. / Mid-Cap Biopharma ($1-$50 billion)

Licensee

This is a sample profile. To view the full content of this profile and many others, log in to BCIQ or sign up for a free trial today!

Active

Sample

01/01/2009

announced